Boulevard Bio launches with $65M seed to chase autoimmune cures

What's the deal? Boulevard Bio has emerged from stealth with a $65 million seed round led by Deerfield ManagementDealroom has a profile for this one. Try Dealroom →. The biotech launches with three drug candidates targeting autoimmune diseases.

What's the endgame? The company is developing a trio of immunology candidates, part of what it describes as a "beautiful path to a cure." The seed capital will fund its early-stage pipeline.

The signal: At $65 million, Boulevard's seed round sits in the top 1% of all seed rounds in health by size — among the roughly 22,700 tracked, only about 0.8% are larger. It reflects DeerfieldDealroom has a profile for this one. Try Dealroom →'s willingness to write big early checks in immunology, a field drawing heavy investor interest.

Read more: Fierce Biotech

Image credit: Generated with Gemini